1372195-69-1

Basic information

• Product Name: 2-bromo-1,3-dimethyl-5-(3-(methylsulfonyl)propoxy)benzene
• Synonyms: 2-bromo-1,3-dimethyl-5-(3-(methylsulfonyl)propoxy)benzene
• CAS NO: 1372195-69-1
• Molecular Formula: C₁₂H₁₇BrO₃S
• Molecular Weight: 321.23058
• Mol File: 1372195-69-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 482.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.380±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-bromo-1,3-dimethyl-5-(3-(methylsulfonyl)propoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1,3-dimethyl-5-(3-(methylsulfonyl)propoxy)benzene(1372195-69-1)
• EPA Substance Registry System: 2-bromo-1,3-dimethyl-5-(3-(methylsulfonyl)propoxy)benzene(1372195-69-1)

Safety Data

• Hazardous Substances Data: 1372195-69-1(Hazardous Substances Data)

Upstream product

• 109-79-5 n-butanethiol 
• 7463-51-6 4-bromo-3,5-dimethylphenol 
• 505-10-2 3-(methylthio)-1-propanol 
• 263400-88-0 3-(methylsulfonyl)propyl 4-methylbenzenesulfonate 
• 1000414-12-9 (3-(4-bromo-3,5-dimethylphenoxy)propyl)(methyl)sulfane 

Downstream Products

• 1000413-85-3 (2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1‘-biphenyl]-3-yl)methanol 
• 1000413-84-2 2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-carbaldehyde 
• 1000413-72-8 [(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid 
• 1234474-57-7 [(3R)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid 
• 1394138-49-8 3'-(chloromethyl)-2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)-1,1'-biphenyl 
• 1394138-50-1 [6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-1-benzofuran-3-yl]acetic acid 
• 1544739-75-4 (5aR,6S,6aS)-ethyl 3-((2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544739-77-6 (5aR,6S,6aS)-ethyl 3-((2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-78-7 ethyl 3-((2’,6’-dimethyl-4’-(3-(methylsulfonyl)propoxy)-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1458653-87-6 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458657-24-3 2-((S)-6-((R)-4-(2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 

Relevant articles and documents

(S) - 2 - (2,3-dihydrobenzo-furan-3-yl) acetic acid derivatives, its preparation process and its use in medicine

The invention relates to an (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative, a preparation method of the derivative, a medicine composition containing the derivative and the application of the derivative serving as a therapeutic agent, particularly GPR40/FFA1, and particularly provides the (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative shown in a general formula (I), and pharmaceutically acceptable salts of the derivative or a prodrug of the derivative. The compound is an agonist of a GPR40/FFA1 receptor and has a good preventive and therapeutic effect on lots of GPR40-mediated diseases, especially diabetes mellitus. The invention also provides a preparation method of the compound.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS

The present invention relates to compounds of general formula I, (I) wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.